Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial (vol 22, pg 29, 2021)

被引：0
|
作者：
Bahadoer, R. R.
Dijkstra, E. A.
van Etten, B.
机构：
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E42 / E42
页数：1
相关论文
共 43 条
  • [31] ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
    Borelli, Beatrice
    Conca, Veronica
    Carullo, Martina
    Sainato, Aldo
    Mattioni, Roberto
    Manfredi, Bruno
    Balestri, Riccardo
    Buccianti, Piero
    Morelli, Luca
    Rossi, Piercarlo
    Vagli, Paola
    Prete, Alessandra Anna
    Luca, Frassineti
    Morano, Federica
    Di Donato, Samantha
    Salvatore, Lisa
    Bengala, Carmelo
    Rossini, Daniele
    Boni, Luca
    Antoniotti, Carlotta
    Masi, Gianluca
    Cremolini, Chiara
    Moretto, Roberto
    CLINICAL COLORECTAL CANCER, 2023, 22 (03) : 339 - +
  • [32] Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study
    Lin, Zhenyu
    Zhang, Peng
    Tao, Kaixiong
    Zhang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
    Roedel, Claus
    Graeven, Ullrich
    Fietkau, Rainer
    Hohenberger, Werner
    Hothorn, Torsten
    Arnold, Dirk
    Hofheinz, Ralf-Dieter
    Ghadimi, Michael
    Wolff, Hendrik A.
    Lang-Welzenbach, Marga
    Raab, Hans-Rudolf
    Wittekind, Christian
    Stroebel, Philipp
    Staib, Ludger
    Wilhelm, Martin
    Grabenbauer, Gerhard G.
    Manns, Hans Hoff
    Lindemann, Fritz
    Schlenska-Lange, Anke
    Folprecht, Gunnar
    Sauer, Rolf
    Liersch, Torsten
    Sauer, R.
    Hohenberger, W.
    Fietkau, R.
    Lahmer, G.
    Golcher, H.
    Klautke, G.
    Hartmann, A.
    Rau, T.
    Keilholz, L.
    Henneking, K.
    Muehldorfer, S.
    Klein, S.
    Stolte, M.
    Staar, S.
    Lehnert, T.
    Hertenstein, B.
    Freys, S. M.
    Pflueger, K.-H.
    Sendt, W.
    Teyssen, S.
    Latz, D.
    Leibl, B. J.
    Matek, W.
    Grabenbauer, G. G.
    Alfrink, M.
    Kreczy, A.
    Strobel, G. F.
    Düwel, H.-J.
    LANCET ONCOLOGY, 2015, 16 (08): : 979 - 989
  • [34] Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT).
    Lin, Zhenyu
    Zhang, Peng
    Zhao, Lei
    Ma, Hong
    Liu, Hongli
    Liu, Junli
    Xu, Ximing
    Lin, Dandan
    Zhang, Zhen
    Xia, Fan
    Tao, Kaixiong
    Zhang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 192 - 192
  • [35] Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.
    Wang, Xin
    Liu, Ping
    Xiao, Yi
    Meng, Wenjian
    Tang, Yuanling
    Zhou, Jitao
    Ding, Pei-Rong
    Ding, Ke-Feng
    Wang, Biao
    Guo, Qing
    Sun, Hao
    Qiu, Jian
    Yu, Yongyang
    Wu, Bing
    Zeng, Hanjiang
    Deng, Xiang-bing
    Jiang, Dan
    Shen, Ya-li
    Zhou, Zongguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3511 - LBA3511
  • [36] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial (vol 19, pg 295, 2018)
    de Boer, S. M.
    Powell, M. E.
    Mileshkin, L.
    LANCET ONCOLOGY, 2018, 19 (04): : E184 - E184
  • [37] Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (vol 391, pg 748, 2018)
    Powles, T.
    Duran, I
    van der Heijden, M.
    LANCET, 2018, 392 (10156): : 1402 - 1402
  • [38] Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial
    Jiang, Weizhong
    Chi, Pan
    Tao, Kaixiong
    Xu, Dongbo
    Yang, Chunkang
    Zheng, Rong
    Xu, Benhua
    Huang, Ying
    Chen, Zhifen
    Huang, Shenghui
    Xu, Zongbin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial (vol 376, pg 687, 2010)
    Bang, Y-J
    Van Cutsem, E.
    Feyereislova, A.
    LANCET, 2010, 376 (9749): : 1302 - 1302
  • [40] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (vol 398, pg 1344, 2021)
    Felip, Enriqueta
    Altorki, Nasser
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Voong, David
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Bennett, Elizabeth
    Gitlitz, Barbara
    Wakelee, Heather
    LANCET, 2021, 398 (10312): : 1686 - 1686
12345